Drugs / CAR-BCMA T cells
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03716856 | Mar 2018 → Jun 2020 | refractory plasma cell neoplasm | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03380039 | Oct 2017 → Jul 2020 | refractory plasma cell neoplasm | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-BCMA T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03716856 ↗ |
| Modality | Cell therapy | “autologous T cells transduced with a BCMA-targeted chimeric antigen receptor (CAR-BCMA T cells)” NCT03380039 ↗ |
| Route | Intravenous | “Route of administration: Intravenous injection.” NCT03380039 ↗ |